Rockwell Medical (NASDAQ:RMTI) Earns Buy Rating from Analysts at Rodman & Renshaw

Rodman & Renshaw assumed coverage on shares of Rockwell Medical (NASDAQ:RMTI) in a report published on Thursday, MarketBeat reports. The firm issued a buy rating and a $5.00 price objective on the stock.

Other equities research analysts have also issued reports about the company. HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Rockwell Medical in a report on Wednesday, September 11th. StockNews.com raised Rockwell Medical from a “hold” rating to a “buy” rating in a research note on Wednesday.

Rockwell Medical Price Performance

Shares of Rockwell Medical stock opened at $2.36 on Thursday. The company has a current ratio of 2.41, a quick ratio of 1.60 and a debt-to-equity ratio of 0.33. Rockwell Medical has a 52-week low of $1.16 and a 52-week high of $5.15. The stock has a 50-day simple moving average of $3.68 and a 200-day simple moving average of $2.61.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Concurrent Investment Advisors LLC bought a new position in Rockwell Medical in the 3rd quarter worth approximately $40,000. Verus Capital Partners LLC bought a new position in Rockwell Medical in the 3rd quarter worth approximately $51,000. Barclays PLC bought a new position in Rockwell Medical in the 3rd quarter worth approximately $90,000. Beacon Financial Advisory LLC bought a new position in Rockwell Medical in the 3rd quarter worth approximately $98,000. Finally, XTX Topco Ltd increased its position in Rockwell Medical by 45.7% in the 3rd quarter. XTX Topco Ltd now owns 28,455 shares of the company’s stock worth $113,000 after buying an additional 8,922 shares during the period. 23.31% of the stock is owned by institutional investors.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.